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Abstract  
Systematic literature reviews of health related quality of life (HRQoL) evidence that are to inform 
economic models can be challenging due to the volume of hits identified in searches using generic 
terms for HRQoL.   Nevertheless, a robust review of the literature is required to ensure that the 
health state utility values (HSUV) used in the economic model are the most appropriate available.  
This article provides a synopsis of literature relating to identifying, reviewing and synthesising 
HSUVs.   
 
The process begins with scoping the needs of the economic model including the definitions of health 
states and the requirements of any reimbursement agencies.  A sequence of searches may be 
required as the economic model evolves.  The terminology used for HRQoL measures may be 
problematic and as there is no robust HRQoL filter (equivalent to that applied for RCTs), sifting the 
results of sensitive searches can be resource intensive.  Alternative approaches such as forward and 
backward citation searches may reduce the resources required while maintaining the integrity of the 
search. 
 
Any included studies should be assessed in terms of quality using a recommended checklist and 
insufficient detail in the primary studies should be noted as a short-coming in this exercise.  Subject 
to homogeneity (similar populations, same measure and preference weights) evidence can be 
pooled in some way, although methodological research into the appropriateness of alternative 
techniques for meta-analysis is in its infancy.  Reporting standards are key and as a minimum should 
include details on searches, inclusion/exclusion criteria (together with rationale for exclusion at each 
stage), assessment of quality and relevance of included studies, and justification for the choice of 
final HSUVs. 
 
Key points for decision makers 
x A variety of resources and methods should be used to identify studies including relevant 
electronic databases, reference list searches, key author and citations searches and contact 
with experts. 
x Identification of evidence may be an iterative process and should be informed by the 
decision model and requirements of relevant reimbursement agencies. 
x As searches and inclusion criteria are likely to evolve overtime, records of searches and 
exclusion rationale should be well documented and final selection should be justified. 
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1. Introduction 
Health state utility values (HSUVs) are important parameters in economic models and with an ever 
increasing evidence base it is becoming increasingly important to demonstrate that the HSUVs are 
identified and selected using a systematic and transparent method.  However, modelling reports 
frequently provide very sparse descriptions of the HSUVs used and rarely document the source or 
justify the values selected[1].   
 
This article provides an overview of the current literature relating to identifying and reviewing 
HSUVs from the literature, together with details on when and how to synthesise the evidence.  A 
case-study of a review in osteoporosis related conditions is used for demonstration purposes.  The 
study aimed to systematically review published HSUVs for osteoporotic fractures (hip, clinical, and 
morphometric vertebral, wrist, shoulder, and the interaction of several fractures) to determine the 
associated loss of utility for use in future decision analytic models [2,3]. Full details of this study are 
reported elsewhere [2,4,5].  Checklists and recommendations for reviewing published HSUV evidence 
are provided.  Terminology used in this article includes: 
x Sensitivity  W the ability of the literature search to find all relevant material 
x Precision  W the ability of the literature search to reject irrelevant material 
 
2. Scoping the review 
As the aim of the review is to populate the health states within a decision analytic model, prior to 
embarking on the review, it is essential to fully scope the needs of the model as far as is possible to 
determine the HSUVs required.  This includes the health states defined within the model and the 
requirements of any reimbursement agencies that will use the results generated to inform policy 
decision making. Whilst the scoping stage will arrive at a clear understanding of the required HSUVs 
at the outset of the review, a degree of iteration and scope refinement is possible as the model 
development process progresses.   Figure 1 provides details on the possible stages in the systematic 
reviewing process. 
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Figure 1  Reviewing HSUVs  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: Reprinted from Papaioannou et al. [5], page 687, with permission from Elsevier 
 
2.1 Health states within the model 
Decision analytic models describe the clinical pathway of a condition through the use of discrete 
health states.  These models can become quite complex with multiple health states representing: 
the progression of the underlying condition (such as decreases in function and increases in pain 
levels as observed in arthritic conditions), condition related comorbidities (such as onset of 
cardiovascular disease in diabetes), discrete events (such as different fractures in osteoporosis), 
adverse events associated with the interventions (such as gastrointestinal problems for people on 
Scoping the review 
Literature searching 
Ideally including: 
x Electronic databases 
x Reference list checking 
x Contact with experts 
x Citation searching 
 
Scope refinement 
x Exploring HSUV data available 
x Refining inclusion/ exclusion criteria 
Full data extraction 
Selection of studies 
Choice of appropriate values for 
decision model 
Consideration of data synthesis 
Data presentation 
Quality and 
relevant 
assessment 
More health 
states requiring 
HSUVs emerge 
Preliminary 
data extraction 
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long-term steroid use), or conversely, additional benefits beyond the condition of interest (for 
example, bisphosphonates provided to treat osteoporosis may also reduce the risk of breast cancer, 
and bone loss in periodontal disease).  Figure 2 provides the possible health states in a model in 
osteoporosis.  The time horizon used can affect requirements as can be seen in Figure 2 where the 
HSUV immediately post fracture may differ from the HSUV at one year post fracture.  Additional 
HSUVs may also be required as the economic model evolves over time.  
 
Figure 2  HSUV data needs in the osteoporosis case-study  
Health states Disease stage 
x Pre-fracture (age and sex matched norms) 
 
                                                                    With vertebral deformity 
x Established osteoporosis 
                                                                     Without vertebral deformity 
Fracture history 
x With a history of fracture 
x Without a history of fracture 
 
Fracture type 
x Vertebral fracture (with clinical input) 
x Hip 
x Shoulder                                                                Time 
x Wrist                                                                      post-fracture 
x Multiple fractures 
 
Non-osteoporosis health states 
x Breast cancer 
x Atrial fibrillation 
x Bone loss in periodontal disease 
Population subgroups Age group 
 
Menopausal state 
x Pre-menopausal 
x Post-menopausal 
Other considerations Setting 
x Nursing home 
x Independent living 
Source: Reprinted from Papaioannou et al. [5], page 689, with permission from Elsevier 
 
2.2 The type of evidence required 
The type of evidence required may be dictated by the decision maker/reimbursement authority [6].  
For example, while the National Institute for Health and Care Excellence NICE in the UK states a 
preference for the EQ-5D evidence where possible, other agencies do not place similar restrictions 
6 
 
ŽŶƚŚĞƚǇƉĞŽĨĞǀŝĚĞŶĐĞĂŶĚĂƐŬƚŚĂƚƚŚĞƐĞůĞĐƚŝŽŶŽĨĞǀŝĚĞŶĐĞƵƐĞĚŝŶƐƵďŵŝƐƐŝŽŶŝƐ ?ũƵƐƚŝĨŝĞĚ ? ?Ğ ?Ő ?
Canadian Agency for Drug and Technologies in Health (CADTH) in Canada) [7].   
 
The hits obtained from searches for HSUVs can be notoriously large as the evidence base is not 
restricted to randomised control trials (RCTs).  HSUVs can be obtained from various measures (e.g. 
condition-specific preference-based measures (CSPBMs) or generic preference-based measures 
(GPBMs)) [8,9] and restricting the searches to a particular measure may help with managing the 
number of possible hits from searches.  However, introducing a filter (such as EQ-5D) too early in the 
scoping phase may limit the usefulness of the search resulting in no studies being selected for 
review.  Consequently, if there is a specific requirement (such as EQ-5D in the first instance), a 
scoping search to gauge the size of the likely evidence is recommended.  If the initial scoping search 
identifies no evidence which satisfies the requirements of both the reimbursement authority and the 
model, then a broader search strategy will be required (perhaps expanding the GPBM beyond the 
initial preferred measure).  It should be borne in mind that it may be possible to map from the 
measure collected in a clinical efficacy study to the preference-based measure required by the 
agency [10]. 
 
2.3 Appropriateness of existing systematic reviews 
Existing systematic reviews, such as those published as journal articles, or reviews in previous Health 
Technology Assessment (HTA) submissions can provide the required HSUVs, or they can be used as 
the starting point of a future search strategy.  Any scoping searches should be sufficiently sensitive 
to identify this form of evidence.  However, prior to using the HSUVs reported within the review, or 
using the search strategies used in the review to inform the new searches, the review needs to be 
assessed in terms of quality and in particular: are the identification and selection methods 
systematic and transparent and has the evidence reported been appraised satisfactorily.  An 
adapted version of the CASP checklist (Table 1) [is recommended in the latest NICE Technical 
Support Document (TSD) and the unmodified version is reproduced in full in the TSD [4]. 
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Table 1  Quality assessment checklist for systematic reviews of HSUVs 
   Tick as appropriate 
   Yes No Partly ĂŶ ?ƚƚĞůů 
1. Did the review ask a clearly-focused question?     
 Consider if the question is focused in terms of:     
  Population describing the health state (ideally patients)     
  Population valuing the change in HRQoL (ideally public)     
  Method of elicitation (ideally choice-based method e.g. TTO)     
2. Did the review include the right type of study?     
 Consider if the included studies:     
  ĚĚƌĞƐƐĞĚƚŚĞƌĞǀŝĞǁ ?ƐƋƵĞƐƚŝŽŶ     
  Are appropriate studies     
3. Did the review try to identify all relevant studies?     
 Consider as a minimum:     
  Were a number of electronic databases searched? 
(ideally clinical and specific health economic) 
    
  Were reference lists scrutinised for retrieved references?     
 Ideally, but not mandatory, consider that the search methods should involve:     
  Personal contact with experts     
  Search for unpublished studies     
  Citation and author searches     
4. Did the review assess the quality of the included studies?     
 Consider the:     
  Sample size     
  Respondent selection and recruitment     
  Inclusion/exclusion criteria     
  Response rates to instrument used     
  Numbers (%) lost to follow-up     
  Are reasons provided for any loss to follow-up     
  How is missing data from the instruments used to describe the health states dealt with? Is the 
method rigorous? 
    
  Any other problems with the study?     
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   Tick as appropriate 
   Yes No Partly ĂŶ ?ƚƚĞůů 
5. Did the review assess the relevance of the included studies to the review question?     
  Population describing the health state (ideally patients)     
  Population valuing the change in HRQoL (ideally public)     
  Method of elicitation (ideally choice-based method e.g. TTO)     
6. If the results of the studies have been combined, was it reasonable to do so?     
  The results of each study are clearly displayed     
  The results were similar from study to study (look for tests of heterogeneity)     
  The reasons for any variation in results are discussed     
7. How are the results presented, and what is the main result?     
  Is there a full account of why studies were excluded? (includes factors relating to relevance)     
  Is there full justification of why studies were included?     
  How are the results expressed (descriptive statistics or coefficients of a model)     
8. How precise are the results?     
 Consider:     
  If confidence intervals (CI) were reported. Would your decision about whether or not to use 
this INTERVENTION be the same at the upper CI as at the lower CI? 
    
  If a p-value is reported where Cis are unavailable     
9.  Can the HUSVs be used for the health states in your decision model?     
 Consider:     
  How relevant the population describing the health state is to the health state in the decision 
model 
    
  Have all subgroups been considered e.g. age, disease severity, setting     
  Do the HSUVs match the REQUIRED reference case     
  How do the results need to be modified for the decision model?     
Source: Adapted from CASP[
11
] and Papaioannou et al.[
5
], page 694, with permission from Elsevier  Key: CI  W confidence interval; HRQoL  W health related quality of life; 
HSUV  W health state utility value; TTO  W time trade off. 
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3. Literature searching 
Empirical evidence describing optimal approaches when searching for HSUVs is sparse, and 
methodological guidance used for reviews of clinical effects do not generalise to HSUVs.  In addition, 
while there are several filters that can be used to limit the type of study design (e.g. RCT), there is no 
known validated methodological search filter for HSUV evidence although some exploratory work is 
being undertaken [12].  This absence of an established filter is partly due to the variety of potential 
sources (in addition to RCTs, HSUVs may also be reported in observational studies, cost-effectiveness 
analyses, HTA reports and industry submission documents).  The ideal search would take a sensitive 
approach using a comprehensive search strategy encompassing a variety of sources (multiple 
electronic databases) supplemented by additional techniques such as citation searches and 
reference list checks.  However, sensitive searches of this nature can be resource intensive in terms 
of sifting the potential hits identified.  An alternative, which retains the systematic and replicable 
nature of the search, may be to restrict the main search in the expectation that the supplementary 
search techniques are likely to detect most unidentified evidence. 
 
Searches for HSUVs are likely to involve a sequence of searches as the model evolves (the numbers 
or definitions of the health states within the model increase or change respectively), and the results 
of the initial literature searches identify gaps in the required evidence.  Consequently, records of the 
individual searches and the selections from the corresponding results should be maintained to 
increase transparency of the process.  Three core issues (search terms, where to search, and 
supplementary searches) that arise when searching for HSUVs are discussed below. 
 
3.1 Search terms 
While the terminology for the health states within the decision model is relatively straightforward 
(examples from the 28 possible health states in Figure 2: established osteoporosis with vertebral 
deformity, fracture of the hip, fracture of the shoulder, fracture of the wrist, etc.) the terminology 
for the health related quality of life (HRQoL) measures (i.e. the particular HSUVs required), can be 
more problematic in terms of both subject headings and the presence of relevant words in titles and 
abstracts. 
 
Subject headings: The common GPBMs (i.e. EQ-5D, SF-6D, and HUI) do not have dedicated thesauri 
terms in Medline (MeSH) and Embase (EMTREE), and relevant studies can be indexed under broader 
ĐŽŶĐĞƉƚƐŶŽƚŽďǀŝŽƵƐůǇĂƉƉůŝĐĂďůĞƚŽ ŝĚĞŶƚŝĨǇŝŶŐ,^hsƐƐƵĐŚĂƐ  ?ƋƵĂůŝƚǇŽĨ ůŝĨĞ ?Žƌ  ?ƋƵĂůŝƚǇĂĚũƵƐƚĞĚ
ůŝĨĞǇĞĂƌ ? ?Y>z ? ?&ŽƌĞǆĂŵƉůĞ ?ǁŚĞŶƵƐŝŶŐ,^hs-related free-text terms to identify a cross-sectional 
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sample of 300 records from Medline, the following indexing terms (in order of frequency) were 
identified: quality of life, questionnaires, psychology (subheading), health status, health status 
indicators, activities of daily living, health surveys, quality-adjusted-life-years, treatment outcome,  
psychometrics [13].  In the osteoporosis case-study review, of the 28 studies included, 24 were 
ŝŶĚĞǆĞĚŽŶDĞĚůŝŶĞ ?ĂŶĚŽĨƚŚĞƐĞ ? ?ƐƚƵĚŝĞƐĂůůďƵƚŽŶĞǁĞƌĞĂƐƐŝŐŶĞĚ ?YƵĂůŝƚǇŽĨůŝĨĞ ?ĂƐƚŚĞDĞ^, 
ƚĞƌŵ ?tŚŝůĞĞŝŐŚƚŽĨƚŚĞ ? ?ƐƚƵĚŝĞƐǁĞƌĞĂůƐŽĂƐƐŝŐŶĞĚƚŚĞDĞ^,ƚĞƌŵ ?ƋƵĞƐƚŝŽŶŶĂŝƌĞƐ ? ?ƚŚĞŵĂũŽƌŝƚǇ
of the other MeSH terms listed previously were not assigned to the studies in the case-study. 
 
Although this example may suggest that ƚŚĞ ƵƐĞ ŽĨ  ?YƵĂůŝƚǇ ŽĨ ůŝĨĞ ? Žƌ  ?YƵĞƐƚŝŽŶŶĂŝƌĞƐ ? ĂƐ DĞ^,
terms in reviews for HSUVs  may achieve a highly sensitive retrieval of relevant studies this likely to 
be coupled with very low precision, increasing the number of irrelevant studies retrieved 
substantially.  There is always a trade-off between increasing the sensitivity or precision of searches, 
and this is particularly relevant for HSUVs where there are no useful validated terms that can be 
applied to filter results for studies reporting HSUVs. 
 
Free-text searching: Appropriate free text terms are encompassed under three broad categories: 
general terms such as QALY and HSUV; instrument specific terms such as EQ-5D and SF-6D, and 
terms describing the methods of elicitation such as time trade off and standard gamble.  Terms may 
be spelled differently, or the full names of measures may be used as opposed to the normal acronym 
(e.g. EQ-5D, eq5d, euoroqol, euro qol etc.) and exemplars of relevant free-text terms used in 
electronic databases are provided in Figure 3.  Searches using free-text terms rely on their presence 
in the title or abstract but as HSUVs are frequently reported as secondary outcomes, they may not 
be mentioned in either and relevant studies will be missed.  In the case-study in osteoporosis, of the 
24 studŝĞƐŝŶĚĞǆĞĚŽŶDĞĚůŝŶĞ ? ? ?ŝŶĐůƵĚĞĚ ?ƋƵĂůŝƚǇŽĨůŝĨĞ ? ŶƚŚĞƚŝƚůĞĂŶĚ ?ĐŽŶƚĂŝŶĞĚ ?ƋƵĂůŝƚǇŽĨůŝĨĞ ?
in the abstract.  Twenty two of the 24 included free text terms in either their title or abstract that 
related to the specific measure used to collect HSUVs. 
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Figure 3  Frequently used free-text terms for HSUVs when searching electronic databases  
quality adjusted life 
quality-adjusted-life (note not all databases can hope with hyphens) 
(qaly$ or qald$ or qale$ or qtime$) 
disability adjusted life 
daly$ 
health$ year$ equivalent$ 
hsuv$ 
utilit$ 
(hql or hqol or h qol or hrqol or hr qol) 
(hye or hyes) 
disutili$ 
disbenefit$ 
preference-based measure$ 
generic measure$ 
gpbm$ 
preference elicit$ 
quality adj2 wellbeing 
qwb 
 
(sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shortform 
thirtysix or shortform thirty six or short form thirtysix or short form thirty six) 
(sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six) 
(sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or sftwelve or shortform twelve or 
short form twelve) 
(sf6D or sf 6D or short form 6D or shortform 6D or sf six D or sfsixD or shortform six D or 
short form six D) 
(sf20 or sf 20 or short form 20 or shortform 20 or sf twenty or sftwenty or shortform twenty or 
short form twenty) 
(euroqol or euro qol or eq5d or eq 5d) 
(hui or hui1 or hui2 or hui3) 
 
Discrete choice 
Dce$ 
standard gamble$ 
SG 
time trade off 
time tradeoff 
tto 
 
Key 
$ =truncation (In some databases this is *) e.g. utilit$ searches for utility or utilities 
adj= adjacency operator. e.g. adj2= within two words of each other 
Source: adapted from Papaiannou et al. [
5
], page 691, with permission from Elsevier 
 
3.2 Sources to search 
The main source for identifying studies containing HSUVs is electronic databases.  In addition to the 
main health-related databases and conference proceedings, specialist health economic resources 
can provide additional relevant studies (Table 2). 
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Specialist sources include the Tufts Cost-effectiveness Analysis (CEA) Registry, the Health Technology 
Assessment database (HTA) and the NHS Economic Evaluation Database (NHS EED). The latter is no 
longer being updated but nonetheless remains a useful resource.  An additional resource is 
ScHARRHUD (http://www.scharrhud.org), a free, searchable web-based database developed and 
managed by ScHARR at the University of Sheffield.  The database holds bibliographic details of 
studies reporting HSUVs.  ScHARRHUD is searchable by the names of the health state valuation 
instruments used in each study.  In providing this level of indexing, ScHARRHUD aims to make the 
retrieval of health utilities evidence both more efficient and effective.  Whilst the focus of 
ScHARRHUD is on GPBMs, such as the EQ-5D, the database extracts and indexes the names of all 
instruments used in studies. Whilst none of these specialist sources claim to be comprehensive, they 
do, collectively, provide a useful focus on the retrieval of HSUV evidence. 
 
Table 2  Sources searched to identify studies including HSUVs 
Electronic Databases: 
Main health-related databases 
 MEDLINE  
 EMBASE  
 CENTRAL  
Conference Proceedings 
 ISI Proceedings  
 ISPOR 
ISOQoL 
Google Scholar 
 
Additional specialist health economic resources 
 Tufts Cost-effectiveness Analysis Registry  
(former Harvard Cost-Effectiveness Analysis database) 
http://healtheconomics.tuftsmedicalcenter.org/cear4/Home.aspx  
 
 Centre for Reviews and Dissemination databases: NHSEED and HTA 
https://www.crd.york.ac.uk/CRDWeb/  
 
   
 The EQ-5D Website / other instrument sites 
http://www.euroqol.org/about-eq-5d.html 
 
 MAPI Research Trust (including the PROQOLID database) 
http://mapi-trust.org/ 
 
 Submissions to NICE or other health care decision agencies (e.g. Canadian 
Agency for Drugs and Technologies in Health (CADTH), Haute Autorite de Sante 
(HAS), Pharmaceutical Benefits Advisory Committee (PBAC),  ) 
 
   
 ScHARR Health Utilities Database (ScHARRHUD) 
http://scharrhud.org/ 
 
Supplementary search techniques 
 Reference lists of included studies  
 Experts in the area  
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 Citations searching  
 Author searching  
 
 
Supplementary search techniques 
Reviews for clinical studies routinely include additional search techniques such as checking reference 
lists of included studies and contacting experts in the area.  Subsequent relevant studies may also be 
identified by a) searching citations of key relevant articles and b) searching for relevant publications 
of key authors in the area.  These supplementary searches can be beneficial as demonstrated in the 
osteoporosis case-study.  Of the 28 studies included in the review, 13 were identified through 
electronic searches, 8 were identified through references lists of the initial 13 studies, 4 were 
identified through contact with experts, and the final 2 were identified from a previous systematic 
review.   
 
 
3.3 Using a sensitive or precise search strategy 
When identifying publications describing clinical effects, it is important to maximise the sensitivity of 
the search.  Consequently a range of synonyms for every concept are used in the search terms and 
an extensive search strategy is used as standard.  The primary disadvantage of a sensitive search 
strategy is the potentially large number of results and the associated resources required.  This is 
particularly relevant for HSUV searches.  For example in the case-study, the use of ƚŚĞƚĞƌŵ ?ƋƵĂůŝƚǇ
ŽĨ ůŝĨĞ ? ŝŶĐƌĞĂƐĞĚƚŚĞŶƵŵďĞƌŽĨŶŽŶ-relevant articles (i.e. produced a large set of results of lower 
precision).  In addition, as discussed earlier, the nonspecific thesauri terms for HSUVs means that an 
extensive search strategy may not ensure that all relevant studies are identified, even when indexed 
on MEDLINE, as demonstrated in the case-study.  
 
Taking a more pragmatic approach by using free-text terms for the relevant HRQoL measures and 
the omission of nonspecific MESH thesauri terms may be considered acceptable when used in 
conjunction with the supplementary search techniques (i.e. citation and reference searching etc.).   
 
The full search strategy used to identify HSUVs for the case-study is provided in the NICE TSD 9 [4,5], 
and associated Supplemental Materials are available at: 
www.nicedsu.org.uk/TSD9%20HSUV%20values_FINAL.pdf   
http://dx.doi.org/doi:10.1016/j.jval.2013.02.017 
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4. Inclusion/exclusion criteria when selecting studies for inclusion in the review 
As in any review, eligibility criteria are defined prior to sifting results.  Results are screened for 
inclusion against eligibility criteria using the standard stages (title, abstract, and full-text) and articles 
can be excluded if they do not meet one or more of the inclusion criteria at each sifting stage.  
However, with HSUV studies, there is an increased risk of excluding relevant studies at the 
title/abstract stage due to the non-standard reporting standards.  For example, in the case-study, 8 
of the studies identified by reference list checks had been excluded at the initial study selection 
stage (prior to full-text retrieval).   In addition Table 3 provides the inclusion criteria used in the case-
study. 
 
The downside of using non-exacting inclusion criteria is the increase in the number of full-text 
articles reviewed, which is compounded when iterative searches are performed to satisfy any 
revised requirements for the updated decision model. 
 
 
Table 3  Inclusion criteria used in the case-study in osteoporosis 
Inclusion criteria 
 Adults > 17 years of age 
 Men and postmenopausal women suffering from primary or secondary osteoporosis 
 Empirically estimated HSUVs using a recognised valuation technique (SG, TTO or VAS) 
 English language or translation 
Key: SG: standard gamble; TTO: time trade-off; VAS: visual analogue scale 
 
Papers which report utilities from other studies/papers are not usually included, but used to help 
identify the original source. Care should be taken to highlight separate papers that draw upon the 
same dataset or study.  
 
There may be several sets of HSUVs required depending on the definitions of health states within 
the decision model (e.g. subgrouped by position of fracture in the case-study), and thus the decision 
process could involve multiple sets of potential references. 
 
The appropriate inclusion criteria may be derived iteratively, at the scoping stage, depending upon 
the availability of studies containing relevant HSUVs. This is particularly pertinent to inclusion criteria 
relating to study quality. Whilst study quality will form an important consideration in ultimate study 
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selection decisions, it is difficult to state a priori strict criteria relating to methodological quality. For 
example, where there is little information at all reviewers may wish to include studies based on 
valuation of vignettes, or even clinical judgement, acknowledging and possibly exploring through 
sensitivity analysis the uncertainty that this type of evidence brings with it.. 
 
 
4.1 Preliminary data extraction 
To assist in the study selection process and the refinement of the inclusion and exclusion criteria, it 
is recommended to undertake a preliminary data extraction of the following three key details: 
 
1) The definition of the health of the population  (e.g. age, sex, definition and severity of condition) 
and the individuals who complete the questionnaire (e.g. patient or carer).  The former should 
reflect  the health state definitions of the decision model, the latter should satisfy any 
reimbursement agencies requirements. 
2) Details of the approach used to describe the health states, e.g. GPBM (such as EQ-5D, SF-6D, 
HUI); vignettes or scenarios; or direct measurement by time trade-off (TTO), standard gamble 
(SG) or visual analogue scale (VAS) including whether self-completed or proxy values are used. 
3) Valuation method including who valued the health states (e.g. general public) and how (e.g. the 
elicitation technique such as TTO, SG or VAS). 
 
5. Quality assessment and relevance of included studies 
High quality clinical reviews generally include some form of assessment of the studies included and 
whilst it is equally important to review the quality of studies for HSUV reviews, there are no agreed 
reporting standards that encompass all the types of studies that could include HSUVs. The quality of 
studies included in these types of reviews can be difficult to assess and selecting a checklist based on 
the design of the primary study may be inappropriate. For example HSUVs may be secondary or 
tertiary outcomes in an RCT powered and designed according to a different primary outcome 
measure.  
 
The ISPOR task force on estimating health-state utilities for economic models defined high quality 
HSUV in this context as  “estimates that are aligned with the definitions of the economic model 
health states, are free from known sources of bias, and were measured using a validated method 
appropriate to the condition and population of interest and the perspective of the decision maker 
ĨŽƌǁŚŽŵƚŚĞĞĐŽŶŽŵŝĐŵŽĚĞůŝƐďĞŝŶŐĚĞǀĞůŽƉĞĚ ?[14]. 
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These four main considerations are explored in more detail in Table 4 which provides criteria for 
assessing the relevance and quality of HSUVs.  Ultimately, any quality assessment is reliant on the 
quality of reporting standards in the primary studies included in the review, and if there is 
insufficient detail to assess the quality of the evidence, this should be noted as a shortcoming. 
 
Table 4 Quality assessment and relevance checklist for studies including HSUVs 
Criteria Consideration 
Relevance to the decision problem 
Population 
characteristics  
How closely do the patient characteristics (e.g. age, sex, comorbidities, 
diagnosis, severity of condition) in the study match those modelled and 
those described in the decision problem? 
Respondent selection 
and recruitment 
Does this result in a population comparable to that being modelled? 
Inclusion/exclusion 
criteria 
Do these exclude any individuals? (e.g. the very elderly >80 years old are 
often not included in studies) 
How closely do the inclusion criteria match people who would receive the 
intervention in routine practice? 
Quality assessment - free from bias 
Sample size This is not an exclusion criteria, but the precision of the estimate should 
be reflected in the variance around any estimate used in the decision 
model 
Response rates to the 
measure used 
Are response rates reported and if so are the rates likely to be a threat to 
the validity of the estimated HSUVs for the health states? 
Loss to follow-up How large is the loss to follow-up (e.g. 1 year after fracture) and are 
reasons given? 
Are these likely to threaten the validity of the estimates? 
Missing data What are the levels of missing data and how are they dealt with? 
Are there details on the causes of the missing data? 
Again, could this threaten the validity of the estimates? 
Utility values are measured and valued appropriately 
Appropriate use of 
valuation method 
If valuation methods are used (TTO, SG, DCE, VAS) they are used 
appropriately? 
Does the valuation method provide preference based values anchored at 
1 as equivalent to full health and 0 as equivalent to dead?  
Are adequate details of the valuation method provided to allow 
judgement on appropriateness? 
Appropriate use of 
GPMB 
Are adequate details of the PBM method provided (e.g. details given on 
the version used, the social tariff applied etc.) 
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Was the GPBM delivered as intended? (e.g. wording and response options 
not changed) 
Is the measure used for the group it was intended (e.g. is an adult GPBM 
being used for children? Is EQ-5D-Y used with the adult tariff? Is a CS-PRM 
being applied to the intended group?) 
Appropriate health-
state description 
(vignette) 
If a health state is valued using a vignette can the accuracy of the vignette 
can be established, e.g. the process by which it was derived is described 
In line with reimbursement agency requirements 
Utilities representative 
of the area of remit for 
the agency 
Is the geographical area of recruitment relevant for the reimbursement 
agency (e.g. country patients recruited from)? 
Measure used to 
describe the HSUVs 
Does the measure used to collect the HSUVs match the requirements of 
the decision problem and reimbursement agency? 
Population the HSUVs 
collected from 
Who completes the measure (e.g. patient, proxy, judgement by clinician) 
and does it satisfy the requirements of the decision problem and 
reimbursement agency? 
Mode of administration  W was it standard across participants? Was it in 
line with reimbursement agency requirements? 
Population used to 
value the health states 
within the measure 
Who values the health states (patients, carer, general population) and 
does this satisfy the requirements of the reimbursement authority of 
interest? 
Technique used to 
value the health state 
What technique is used to value the health stated (e.g. TTO, SG) and does 
this satisfy the requirements of the reimbursement authority of interest? 
Source: adapted from Papaioannou et al.[
5
], page 694, with permission from Elsevier 
 
 
 
6. Data extraction 
tŚŝůĞĞĂƌůŝĞƌĂ ?ƉƌĞůŝŵŝŶĂƌǇ ?ĚĂƚĂĞǆƚƌĂĐƚŝŽŶǁĂƐƌĞĐŽŵŵĞŶĚĞƚŽĂŝĚŝŶƚŚĞƐƚƵĚǇƐĞůĞĐƚŝŽŶƉƌŽĐĞƐƐ ?
ŽŶĐĞƐƚƵĚŝĞƐĂƌĞŝĚĞŶƚŝĨŝĞĚĂƐƉŽƚĞŶƚŝĂůĐĂŶĚŝĚĂƚĞƐĨŽƌƚŚĞƌĞǀŝĞǁ ?Ă ?ĨƵůů ?ĚĂƚĂĞǆƚƌĂĐƚŝŽŶƐƚĂŐĞcan 
be undertaken to assist in: informing the inclusion/exclusion of specific studies from the list of 
candidate studies; identifying if it may be possible to synthesise HSUVs and associated factors 
requiring consideration (e.g. heterogeneity); identifying if the ĚĂƚĂŵĂǇƌĞƋƵŝƌĞ ?ŵŽĚŝĨǇŝŶŐ ?ƚŽŵĂƚĐŚ
ƚŚĞĞǆĂĐƚŶĞĞĚƐŽĨƚŚĞŚĞĂůƚŚƐƚĂƚĞƐǁŝƚŚŝŶƚŚĞĚĞĐŝƐŝŽŶŵŽĚĞů ?dŚĞĚĂƚĂĞǆƚƌĂĐƚĞĚŝŶƚŚĞ ?ĨƵůů ?ĚĂƚĂ
extraction process may require replication for each of the individual health states within the model.  
For example, one individual study may provide HSUVs for both the initial effect and the effect one 
year post fracture for numerous fracture sites. 
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As for clinical effectiveness reviews, the data extraction forms are generally review specific, and it is 
recommended to pilot the design to determine the exact data to be extracted.  There are however, 
many variables which are generic such as author, country of publication, study characteristics 
(inclusion/exclusion criteria), sample size, population characteristics (age, sex, condition and 
severity), and study setting.  Information relating to the outcome of interest may differ depending 
on the measure.  While ideally data extraction is undertaken by two independent reviewers and 
cross-checked (with dispute resolved by a third reviewer), in reality, the process is generally 
undertaken by a single reviewer and checked by a second reviewer. 
 
An example data extraction form is provided (Figure 4) and this should be modified to match the 
requirements of the individual review (for example the disease-specific requirements will change for 
other conditions and models). 
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Figure 4  Sample data extraction form 
General information: 
EĂŵĞŽĨĚĂƚĂĞǆƚƌĂĐƚŽƌ Q Q ? Q Q ? Q ? ? Q ? ? ĂƚĞŽĨĚĂƚĂĞǆƚƌĂĐƚŝŽŶ Q Q ? Q Q ? Q ? ? Q ? ? 
Study  
Ref ID 
Study 
details 
(author, 
title, year) 
 
Country of 
respondents 
Study 
design 
Inclusion 
and 
Exclusion 
criteria 
Participant characteristics 
used in study 
Age 
Sex 
Disease severity 
Any other relevant 
characteristics (e,g, the time 
since clinical diagnosis/onset 
of condition)  
      
 
Method of elicitation of HSUVs  W how and who 
e.g. vignettes/ health state descriptive system (EQ-5D), direct 
measurement 
Patient, clinician, general population 
Valuation technique e.g. SG, TTO, VAS, and 
variant of the technique (e.g. Was a prop 
board used? Was top down titration used? 
What was the bottom anchor for the VAS?) 
  
 
Respondent selection and 
recruitment 
Response 
rates 
Reasons for lost to 
follow-up 
Any other potential problems with the study 
    
 
HSUV descriptive statistics: per subgroup    
Sample size/ number of respondents Mean (SD) Median Range 
Source: Papaioannou et al. [
4
] 
 
7. When and how to synthesise evidence  
Methodological research exploring alternative way to synthesise HSUVs is in its infancy and to our 
knowledge, this is not a requirement of any reimbursement agency.  However, if more than one set 
of the required HSUVs are available, and these are sufficiently homogenous (collected from similar 
populations, using the same measure and preference weights) then some form of pooling could be 
considered as a useful way of improving the precision of the estimates used. 
 
Meta-analysis provides a means to pool data collected across a number of studies and produce a 
weighted average of the measure of interest (for example using the inverse of the variance, or 
sample size), thereby generating a more precise measure.  There are two main methods: 
 
x Fixed effects: This assumes that each study is estimating exactly the same value (the one true 
HSUV for the particular group of interest) hence any differences between studies should be 
explained by within study sampling error. 
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x Random effects: This assumes that each study is estimating a slightly different value (the true 
HSUV varies between studies), but the values follow a distribution across studies  W with the 
studies providing a random sample from the distribution of true HSUVs.  Any differences 
between studies should be explained by both within study sampling error and between study 
variation in the true value.  The combined value therefore represents the mean of the possible 
true HSUVs. 
 
Meta-analysis of HSUVs can be performed where a number of studies provide values on the same 
GPBM (such as meta-analysis on EQ-5D values (e.g. Peasgood et al, 2009 for osteoporosis states [2]; 
Doth et al, 2010 for pain states [15]), where the population is sufficiently similar (for example, they 
use levels of severity of a condition (e.g. mild depression) in a consistent manner across studies), and 
HSUVs are derived from the same preference weights (i.e. not using social tariff from different 
countries). 
 
Meta-analysis is problematic where there is too much heterogeneity between values, as likely when 
considering all possible HSUVs for a particular condition.  Whilst there are standard tests for 
heterogeneity within meta-analysis, judgement is also required as to whether it is conceptually 
appropriate to consider combining values generated using different methodologies, and based on 
different populations.  
 
Meta-regression is a technique to explore possible causes of heterogeneity.  The HSUVs are treated 
as the dependent variable with possible causes of heterogeneity explored through covariates, with 
values weighted by the precision of their estimate.  However, modelling HSUVs is complex, and 
needs to address a number of issues:  
x GPBM are a composite of a descriptive system and a social tariff 
x HSUVs use a bounded scale, and cannot go above 1 (nor below the lowest tariff score for 
GPBM) 
x Most HSUV studies report more than one mean HSUV (e.g. patients may complete more 
than one GPBM and they may complete the same GPBM at different times); consequently 
any meta-analysis of HSUVs needs to address the fact that these values will be correlated.  
 
Furthermore, it is unlikely that the search will have identified sufficient mean HSUVs to enable the 
full exploration of possible group differences (which may additionally be inadequately modelled by a 
simple dummy variable).  Meta-regressions with only a few studies and considerable study 
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heterogeneity run the risk of showing false positives [16], hence may be misleading.  Whilst there are 
no hard and fast rules for the appropriate sample size in meta-regression, a ratio of at least ten 
studies to each covariate is often recommended [17]. 
 
Meta-regression may enhance understanding of heterogeneity within identified utility values, but 
should be treated with caution.  Stricter inclusion criteria (although justified) for meta-regression or 
meta-analysis of HSUV, may help dealing with heterogeneity [18]. 
 
8. Presentation of results  
As mentioned earlier, the search strategies and the inclusion / exclusion criteria used in literature 
reviews for HSUVs used in decision models can be an iterative process as the model evolves and the 
initial results are reviewed.  Consequently, it is extremely important to document the process used 
throughout. 
 
8.1 Searches/inclusion and exclusion of articles 
The full search strategy and corresponding results for each of the iterative stages should be provided 
including the exact terms used in the searches, the databases searches, the numbers of hits, the 
number of potential relevant articles obtained from the supplementary searches, and the rational 
for exclusion of individual articles. Much of this information can be provided as appendices or as 
supplementary information depending on the reporting format or requirements of specific reporting 
standards.  Figure 5 is the flow diagram used to illustrate the study selection and exclusions for the 
osteoporosis case-study, which should be reported together with a tabulation of exclusion rational 
applied to the individual studies at each stage. 
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Figure 5 Osteoporosis case study: Statement flow diagram of study selection and exclusion  
Potentially relevant articles identified from 
the electronic search and screened for 
retrieval  
(n = 1000) 
  
  Papers rejected at the title stage 
(n = 386) 
Total abstracts screened  
(n = 614) 
  
  Papers rejected at the abstract stage 
(n = 564) 
Total full papers screened 
(n = 40) 
  
  Full papers excluded 
 (n = 27) 
Total full papers accepted by sifting  
(n = 13) 
  
   
  Expert contacted (n =  4) 
From references (n = 8) 
Pre-2000 (n = 3) 
Total papers included in the review 
(n = 27) 
  
Source: Reprinted from Peasgood et al.[
2
], Figure 1, with permission from Springer. 
 
8.2 HSUVs used in the decision model 
Once the final selection has been made, it is good practice to provide tabulated mean HSUVs (and 
variance) used for each health state within the decision model, together with a full justification for 
its use.  Any alternative values used in sensitivity analyses should be reported (together with the 
rationale for the value chosen e.g. the use of extreme values identified in the literature review).  
dŚĞƌĞĂƌĞŽĐĐĂƐŝŽŶƐǁŚĞŶ,^hsƐŚĂǀĞƚŽďĞ ?ŵŽĚŝĨŝĞĚ ?ŝŶƐŽŵĞǁĂǇƚŽŵĂƚĐŚƚŚĞĚĞĨŝŶŝƚŝŽŶƐŽĨƚŚĞ
health states.  Examples include: when combining HSUVs obtained from individuals with a single 
condition to represent the HSUV for a comorbidity, adjusting for age or an adverse event, or when 
increasing or decreasing the HSUVs to take account of the time since the acute event.  The 
methodology and the rationale for the choice of values used should be reported explicitly and a 
range of sensitivity analyses should be conducted to reflect the uncertainty associated with the 
modified values.  
 
8.3 Quality and relevance assessment 
The checklists (e.g. CASP) completed during the reviewing process should also be available. 
 
9. Summary 
Literature reviews should be conducted early in the development process of the economic model to 
inform the possible impact and magnitude of effect on a particular health condition, and identify 
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appropriate preference-based measures.  Reviews of health related quality of life literature can be 
resource intensive and scoping searches may be a useful technique to assess the sensitivity and 
precision of the search terms.  Searching is an iterative process informed by the health states within 
the decision analytic model which may develop over time.  Thorough and robust reporting is 
required at all stages to justify the final HSUVs selected. 
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